1731 studies found for:    melanoma
Show Display Options
Rank Status Study
21 Completed
Has Results
Vaccine Therapy in Treating Patients With Metastatic Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: QS21;   Biological: IFA (incomplete Freund's adjuvant);   Biological: p946;   Biological: p946/tet-p;   Biological: Tet-p
22 Recruiting CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma
Conditions: Carcinoma of Unknown Primary Origin;   Iris Melanoma;   Medium/Large Size Posterior Uveal Melanoma;   Mucosal Melanoma;   Ocular Melanoma With Extraocular Extension;   Small Size Posterior Uveal Melanoma;   Stage IIB Skin Melanoma;   Stage IIB Uveal Melanoma;   Stage IIC Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIA Uveal Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Skin Melanoma;   Stage IIIC Uveal Melanoma;   Stage IV Skin Melanoma;   Stage IV Uveal Melanoma
Interventions: Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401;   Other: Laboratory Biomarker Analysis;   Biological: Neoantigen-based Melanoma-Poly-ICLC Vaccine;   Other: Pharmacological Study;   Biological: Recombinant Flt3 Ligand
23 Completed
Has Results
Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: aldesleukin;   Biological: gp100 antigen;   Biological: incomplete Freund's adjuvant;   Biological: sargramostim;   Biological: tetanus peptide melanoma vaccine;   Biological: tyrosinase peptide
24 Not yet recruiting Evaluation of Groin Lymphadenectomy Extent For Metastatic Melanoma
Condition: Metastatic Melanoma to the Groin Lymph Nodes
Interventions: Procedure: Inguinal Lymphadenectomy;   Procedure: Ilio-inguinal Lymphadenectomy
25 Recruiting A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma
Condition: High Risk Melanoma
Interventions: Drug: Ipilumimab;   Radiation: Radiation
26 Unknown  A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma
Conditions: Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma
Intervention: Biological: CB-10-01 (Transgenic Lymphocyte Immunization)
27 Completed Study of Circulating Tumor Cells Before and After Treatment in Patients With Metastatic Melanoma
Condition: Melanoma
Intervention: Other: Sampling of blood
28 Unknown  Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma
Conditions: Advanced Melanoma;   Untreated Patients
Interventions: Drug: dacarbazine plus Endostar (Experimental group);   Drug: dacarbazine plus placebo (control group)
29 Completed Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells
Conditions: Metastatic Melanoma;   Absence of CNS Metastases
Intervention: Biological: Proteasome siRNA and tumor antigen RNA-transfected dendritic cells
30 Completed Pilot Study of Infrared Imaging of Cutaneous Melanoma
Condition: Melanoma
Intervention:
31 Unknown  Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
Conditions: High Risk HLA-A2+ Melanoma;   Metastatic Disease
Intervention: Biological: Melanoma vaccine modified to express HLA A2/4-1BB ligand
32 Recruiting Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma
Condition: Melanoma (Skin)
Interventions: Genetic: gene expression analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry;   Other: medical chart review
33 Recruiting Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
Condition: Malignant Melanoma
Interventions: Biological: A2/4-1BBL melanoma vaccine;   Procedure: DNP sensititzation;   Drug: Cyclophosphamide
34 Recruiting Anti‐PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases
Conditions: Melanoma;   Brain Metastases
Interventions: Drug: Nivolumab;   Drug: Ipilimumab
35 Completed Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
Condition: Melanoma
Interventions: Biological: Autologous, DNP-modified vaccine (M-Vax);   Biological: Autologous, DNP-Modified Melanoma Vaccine;   Biological: Autologous, DNP-Modified Vaccine
36 Terminated Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma
Condition: Melanoma
Intervention: Biological: A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1
37 Completed Vaccine Therapy in Treating Patients With Advanced Melanoma
Conditions: Intraocular Melanoma;   Malignant Conjunctival Neoplasm;   Melanoma (Skin)
Interventions: Biological: incomplete Freund's adjuvant;   Biological: multi-epitope melanoma peptide vaccine;   Biological: tetanus toxoid helper peptide;   Procedure: biopsy
38 Terminated
Has Results
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
Conditions: Metastatic Melanoma;   Metastatic Renal Cancer
Interventions: Drug: Zanolimumab;   Drug: Aldesleukin
39 Recruiting Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma
Condition: Metastatic Melanoma
Intervention: Radiation: WBRT
40 Completed Evaluation of a Simulation Training Tool to Identify Lesions Requiring Further Screening for Melanoma
Conditions: Skin Simulation Model;   Mastery Learning Model to Simulation Training for Visual Screening for Melanoma and Skin Biopsy
Intervention: Other: Simulation teaching session

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years